Skip to main content
Mohammad Jahanzeb, et al., The Oncologist
Patients with non-small cell lung cancer (NSCLC) characterized by ALK rearrangements may benefit from ALK tyrosine kinase inhibitor (TKI) therapies. This article summarizes the characteristics of patients with ALK+ advanced NSCLC treated with ALK TKI therapy, describes treatment pathways and duration for these patients, and examines real-world progression-free survival and treatment discontinuation for patients receiving first-line and second-line ALK TKI therapy overall and for the subgroups of patients with and without pre-existing brain metastasis at ALK TKI initiation.
Don Dizon learns about Ginny Mason's experiences as a breast cancer survivor, patient advocate, and nonprofit leader in this month's blog post.
In this month's blog post, Don Dizon and his colleague Mary Anne Fenton discuss her career in oncology and how the profession has changed over the past 20 years.
In this month's blog, Don Dizon and patient advocate Stacey Tinianov reflect on the power words can have when communicating about cancer with patients. They also discuss how the meaning of words can be fluid and dependent on individual context.
As we monitor and respond to the COVID-19 outbreak, we at AlphaMed Press know how important every update and new piece of information is to reaching the goal of ending this pandemic. Below you can find helpful links to the latest research and findings.
Immunotherapy enhances a cancer patient’s immune system to fight an array of cancers. Immune checkpoint blockade can, however, induce inflammatory side effects known as immune-related Adverse Events (irAE). Because these rare but serious complications need to be quickly detected and properly treated, The Oncologist is devoting a new series designed to enhance the care of patients who may well benefit from therapeutic strategies that involve one or more these powerful immunotherapies.
Precision Medicine Clinic: Molecular Tumor Board is a case-based series designed to help clinicians optimize molecular testing for their patients. The Editors of The Oncologist encourage institutions to share their findings and experiences to help improve the precision of genomic oncology and fulfill its promise of improved outcomes for patients. This collection highlights a diverse set of patients exhibiting a range of tumor types and mutations.
Opioids form the cornerstone of pain management in cancer patients, but the crisis of opioid addiction has resulted in significant challenges facing patients, physicians, lawmakers, and communities across the nation. This series is focused to help clinicians manage the opioid crisis while ensuring adequate pain management for their patients.
Copyright © The Oncologist Community 2020. All rights reserved.